Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Lilly also said on the call that it was already building manufacturing capacity for its experimental oral obesity drug, orforglipron, which eased some analyst concerns over the medicine's success.
Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 ...
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback